Final product fill

The final product containers must also be pre-sterilized. This may be achieved by autoclaving or passage through special equipment that subjects the vials to a hot WFI rinse, followed by sterilizing dry heat and UV treatment. 

---

In some instances it may be necessary to demonstrate that all traces of specific contaminants have been removed prior to final product filling. This would be true, for example, of many proteolytic inhibitors added during the initial stages of downstream processing to prevent proteolysis by endogenous proteases. Some such inhibitors may be inherently toxic, and many could (inappropriately) inhibit endogenous proteases of the recipient patient. 

The quantity of resin appHed to the reinforcing ply to achieve a state of full densification varies inversely with the laminating pressure. Therefore, high pressure laminates pressed at about 7 MPa (1000 psi) need only about 25—30% phenoHc resin in kraft paper, whereas low pressure (1 MPa = 145 psi) laminates need 50—60% resin in the reinforcing ply if all voids are to be filled in the final product. 

When the hydrosol ceases to flow like a Hquid (the gel time), it is termed a hydrogel (Fig. 11a). As formed, the pores are filled with the medium (usually water) in which the gel is prepared. The hydrogel may be washed to remove the by-product salt and sold in that form, in which case it may consist of up to 70% water. Because the water is trapped in the pores, the final product can stiU be a relatively free-flowing powder. 

Aseptic Crystallization and Dry Powder Filling. Aseptic crystallization is primarily used for manufacture of sterile aqueous suspensions. However, if the physical form of the drug is critical to quality of the final product, better control over physical form can be attained by aseptic crystallization because a large variety of organic solvents can be used to control the crystallization process. In aseptic crystallization, the drug is... 

Portions of the sun visor arms used in automobiles can be manufactured from glass-filled thermoplastic polymers. Several visor arms contained visible blemishes on the surface. Typically, the steel insert of the visor arm is overmolded with the glass-filled thermoplastic polymer. Manufacturers sometimes utilize striations on the steel insert to provide a mechanical interlock with the over-molded thermoplastic polymer. However, in an improperly controlled environment, the mechanical process that produces the striations can also be the source of contamination and cause surface blemishes in the final product. 

Biopharm production can be divided into upstream and downstream processing (Figure 5.5). Upstream processing refers to the initial fermentation process that results in the initial generation of product, i.e. the product biosynthesis phase. Downstream processing refers to the actual purification of the protein product and generation of finished product format (i.e. filling into its final product containers,... 

Final product formulation Product filling, freeze drying (if required) and sealing -> Labelling and packaging... 

Upstream processing is deemed to commence when a single vial of the working cell bank system (see later) is taken from storage and the cells therein cultured in order to initiate the biosynthesis of a batch of product. The production process is deemed complete only when the final product is filled in its final containers and those containers have been labelled and placed in their final product packaging. 

Filtration of the final product through a 0.22 pm absolute filter in order to generate sterile product, followed by its aseptic filling into final product containers. 

After the product has been filled (and sealed) in its final product container. QC personnel then remove representative samples of the product and carry out tests to ensure conformance to final product specification. The most important specifications will relate to product potency, sterility and final volume fill, as well as the absence of endotoxin or other potentially toxic substances. Detection and quantification of excipients added will also be undertaken. Product analysis is considered in Chapter 7. 

Native factor VIII is traditionally purified from blood donations first screened for evidence of the presence of viruses such as hepatitis B and HIV. A variety of fractionation procedures (initially mainly precipitation procedures) have been used to produce a factor VIII product. The final product is filter-sterilized and filled into its finished product containers. The product is then freeze-dried and the containers are subsequently sealed under vacuum, or are flushed with an inert gas (e.g. N2) before sealing. No preservative is added. The freeze-dried product is then stored below 8 °C until shortly before its use. 

Purification entails use of an immunoaffinity column containing immobilized murine antifactor VII antibody. It is initially produced as an unactivated, single-chain 406 amino acid polypeptide, which is subsequently proteolytically converted into the two-chain active factor Vila complex. After sterilization by filtration, the final product is aseptically filled into its final product containers, and freeze-dried. 

After its purification, sterile filtration and aseptic filling, human urokinase is normally freeze-dried. Because of its heat stability, the final product may also be heated to 60 °C for up to 10 h in an effort to inactivate any undetected viral particles present. The product utilized clinically contains both molecular mass forms, with the higher molecular mass moiety predominating. Urokinase can also be produced by techniques of animal cell culture utilizing human kidney cells or by recombinant DNA technology. 

Sterile filtration and aseptic filling into final product container... 

The rHBsAg is produced in an engineered S. cerevisiae strain and is likely purified subsequent to fermentation by a procedure somewhat similar to that presented in Figure 13.10. The final product is presented as a sterile suspension of the antigen absorbed onto aluminium hydroxide (adjuvant), in either single-use vials or pre-filled syringes. It also contains NaCl and phosphate buffer components as excipients. It is intended for i.m. injection, usually as 10 pg in a volume of 0.5 ml for infants/children or 20 pg (in 1.0 ml) for adults. The normal dosage schedule entails initial administration followed by boosters after 1 and 6 months. 

A 1-1. steel bomb is charged with 200 g. (1.51 moles) of dicyclo-pentadiene (Note 1). The bomb is flushed with ethylene (Note 2) and then filled while shaking to an initial pressure of 800-900 p.s.i. at 25°. Shaking is continued as the bomb is slowly heated (Note 3) to 190-200° and maintained at this temperature for 7 hours (Note 4). At the end of this period, the reaction vessel is cooled and vented, and the crude product is transferred into a simple distillation apparatus (Note 5). A fraction boiling between 93° and 100° is collected, yield 162-202 g. (57-71%, based on dicyclopentadiene) (Note 6). The norbornylene may be redistilled with negligible losses to give a final product, b.p. 94-97°/740 mm., m.p. 44-44.5° (sealed capillary). 

The tank is filled with streams 1 and 2, and when the tank is approximately full, the outlet volumetric flow rate is set to the approximate steady state value, as would be controlled by a pump. This leads to some further volume change as the final product density is reached. 

Molecular weights for the final products were determined by MALDI-TOF-MS or (polyacrylamide) gel electrophoresis (PAGE). They were corroborated by calculated values from AFM dimension data and were found to be in relatively good agreement within this series (Table 27.2). Calculations based on these experimentally determined molecular weights allowed the estimation of shell filling levels for respective core-shell structures within this series. A comparison with mathematically predicted shell saturated values reported earlier [34], indicates these core-shell structures are only partially filled (i.e. 40-66% of fully saturated shell values, see Table 27.2). 

Water represents one of the most important raw materials used in biopharmaceutical manufacture. It is used as a basic ingredient of fermentation media, and in the manufacture of buffers used throughout product extraction and purification. It represents the solvent in which biopharmaceutical products sold in liquid form are dissolved, and in which freeze-dried biopharmaceuticals will be reconstituted immediately prior to use. It is also used for ancillary processes, such as the cleaning of equipment, piping and product-holding tanks. It is additionally used to clean/rinse the vials into which the final product is filled. 

---